Clinical Trial Update: EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) [Phase 3]

View source ↗

Summary

Phase 3 EVOLVE II QCA trial evaluating the SYNERGY Stent System for atherosclerotic lesions has completed and posted results in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• SYNERGY Stent System

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Atherosclerotic Lesion(s) | Phase 3 | Status: COMPLETED | Results posted: 2016-03-16